Trial Search Results
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined.
This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).
Stanford is currently not accepting patients for this trial.
- Radiation: Fractionated Stereotactic Radiosurgery (SRS)
- Procedure: Surgical resection
- Age 18 years and older
- Pathologically-proven solid tumor malignancy
- 1 to 4 brain metastases, one of which is 4.2 to 33.5 cm³.
- Prior surgery or SRS is allowed as long as the target metastatic lesion in this study
has not previously been treated with SRS.
- Prior cytotoxic systemic therapy must be completed ≥ 5 days prior to radiosurgery. No
concurrent cytotoxic systemic therapy along with SRS. Cytotoxic systemic therapy to
start ≥ 5 days after the completion of SRS.
- Life expectancy of ≥ 12 weeks.
- Ability to understand and the willingness to sign a written informed consent.
- Previously treated with whole brain irradiation
- Target metastatic lesion previously been treated with SRS.
- > 4 total brain metastases at the time of initial evaluation.
- Unable to give informed consent.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study